Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Recruiting · NCT05059951 · Observational (researchers observe without assigning treatment) · Lead sponsor: Hunan Province Tumor Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- ≥18，Lung Cancer Confirmed by Histopathology
- Treated with Chemotherapy with or Without Checkpoint Inhibitors.
- ECOG 0 - 1.
- Predicted survival ≥ 12 weeks.
- Adequate bone marrow hematopoiesis and organ function
- Presence of measurable lesions according to RECIST 1.1.
- Subjects with stable brain metastases may be included in the study.
Exclusion criteria
- Patients did not match for the Inclusion Criteria.
Where it is running
1 location listed.
- Hunan Cancer Hospital - Changsha, Hunan, China